AstraZeneca, Gilead merger doubted by Wall Street analysts
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/11/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Wall Street ends higher as investors turn to earnings season
- AppLovin gains market share among e-commerce advertisers
AstraZeneca (AZN) PT Raised to $60 at Cowen
June 10, 2020 8:45 AM EDTCowen analyst Steve Scala raised the price target on AstraZeneca (NYSE: AZN) to $60.00 (from $55.00) while maintaining an Outperform rating after updating the model following recent news including ASCO presentations, additional roxadustat data, and reports that AZN had contemplated a large-scale business... More
AstraZeneca (AZN) CEO Soriot Said to Have Called Gilead (GILD) CEO on May 9, Proposed Exploring Merger to O'Day on Call - Bloomberg
June 8, 2020 5:04 PM EDTAstraZeneca (NYSE: AZN) CEO Soriot Said to Have Called Gilead (NASDAQ: GILD) CEO on May 9, Proposed Exploring Merger to O'Day on Call - Bloomberg
... MoreGilead Sciences (GILD) Worth $120+ in Rumored Takeover - Piper Sandler
June 8, 2020 9:49 AM EDTPiper Sandler analyst Tyler Van Buren reiterated an Overweight rating and $90.00 price target on Gilead Sciences (NASDAQ: GILD) following rumor of a potential deal with AstraZeneca (NYSE: AZN). Van Buren sees Gilead worth $120+ per share in a deal.
The analyst commented, "The... More
